Drug Profile
EOC 317
Alternative Names: ACTB-1003; EDP317; EOC317; MMKI - ACT Biotech; Multi-mode kinase inhibitor - ACT BiotechLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Bayer HealthCare
- Developer ACT Biotech; Eddingpharm
- Class Antineoplastics; Morpholines; Pyrroles; Small molecules; Triazines
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Fibroblast growth factor receptor antagonists; TIE 2 receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Solid tumours
Most Recent Events
- 29 Aug 2018 Chemical structure information added
- 23 Jul 2018 Discontinued - Phase-I for Cancer in USA (PO)
- 23 Jul 2018 Discontinued - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in China (PO)